165 filings
Page 3 of 9
6-K
uovjvjgv171q5ol
10 Jan 22
Galmed announces positive results of Phase 1 study of Amilo-5MER
8:11am
6-K
gno02w
8 Nov 21
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
8:25am
6-K
p2ber o8u1uim
1 Nov 21
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
10:23am
6-K
xw4s7ycs2wh9bjw8ol5
12 Oct 21
Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
7:00am
6-K
e6q8yvlf8d0926664jbm
31 Aug 21
Current report (foreign)
4:30pm
6-K
1rrwws5t e0
23 Aug 21
Current report (foreign)
4:30pm
6-K
6hcq 6f410bytj
19 Aug 21
Galmed Pharmaceuticals Announces Publication in “The Journal of Autoimmunity” for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
8:11am
6-K
fk0vy7rjy jufy9
16 Aug 21
MHRA Agrees with Galmed’s Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
8:31am
6-K
4x1clxl1d5 158jh4ijc
5 Aug 21
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
7:00am
6-K
enqjssn6bs
2 Aug 21
FDA Agrees with Galmed’s Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
7:47am
6-K
jhwzjz683kiwy5xhbl05
19 Jul 21
Current report (foreign)
4:30pm
6-K
s7zsapxe86bl80 7yfk
2 Jul 21
Current report (foreign)
4:30pm
6-K
qc3jx1
13 May 21
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
8:13am
6-K
jh6j89k1 pfn
3 May 21
China to Join Galmed's Phase 3 ARMOR Registrational Study for the Treatment of NASH & Fibrosis
8:42am
6-K
t68nsnosqv2l1
26 Mar 21
Current report (foreign)
5:11pm
6-K
tp71jbohs1sn0
18 Mar 21
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
7:29am
6-K
7ms2ur2k6l9
16 Mar 21
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
8:38am
6-K
aep h35upx
18 Feb 21
Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares
9:26am
6-K
7fh8kg85xoms3yc17tp6
16 Feb 21
Current report (foreign)
4:26pm
6-K
gyqmglb 79c29jcdy
26 Jan 21
Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol's Novel Anti-Fibrotic Mechanism of Action
11:01am